A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
Robert S. DiPaola, Yu Hui Chen, Mark Stein, David Vaughn, Linda Patrick-Miller, Michael Carducci, Bruce Roth, Eileen White, George Wilding
Dive into the research topics of 'A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899'. Together they form a unique fingerprint.